What Is OKYO Pharma Limited (OKYO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, OKYO Pharma Limited's intrinsic value is estimated at a composite fair value of $1.12. Trading at $1.38, the stock is approaching fair value or slight overvaluation (implied return of -18.8%), as 5 of 8 models suggest limited further upside. Notably, First Chicago sees the most upside at +68.3% (fair value: $2.32), while Regime Cross is the most conservative at -91.4% ($0.12). The spread between these extremes — +159.7% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About OKYO?
8 of 13 models are currently active for OKYO. Of these, 3 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates OKYO's intrinsic value at $0.41, implying -70.3% downside from the current price. See which stocks rank higher →
How Does OKYO Rank in Biological Products, (No Diagnostic Substances)?
Among 139 Biological Products, (No Diagnostic Substances) stocks, OKYO ranks #139 by Quality of Company score. CirclFi's QOC score of 2.0/10 evaluates 32 fundamental signals. A score of 2.0 signals below-average fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
OKYO Pharma Limited operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is OKYO a Value Trap?
The Value Trap algorithm is not active for OKYO. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for OKYO Pharma Limited. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, OKYO Pharma Limited scores 2.0 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +159.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every OKYO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across OKYO's 8 active models, average confidence is 9%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad